According to Sirna, the patents cover microRNA technology for the modulation of gene expression, and could strengthen its IP position in the miRNA market. The license is for all uses, including therapeutics, diagnostics, and research reagents, Sirna said.
The patents cover technology invented by UMMS scientists Phillip Zamore and Gyorgy Hutvagner, and provides methods for inhibiting small RNA function, such as microRNA function in vitro and in vivo, Sirna said. The company maintained that the patents "describe methods that can be used not only for advancing RNAi basic research, but also for developing miRNA-based therapeutics. "
The financial terms of the license were not disclosed.